The AMPLITUDE-O trial analysis of Lam et al. highlighted the cardiovascular benefits of efpeglenatide, noting a 27% reduction in major adverse cardiovascular events among patients with high-risk T2DM, especially when combined with SGLT2 inhibitors [14]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.